This cross-sectional study was conducted to examine whether the obstructive sleep apnea syndrome (OSAS) is associated with elevation of the pulse wave velocity (PWV) and increase in the plasma levels of C-reactive protein (CRP), both of which are known markers of cardiovascular risk, and also to determine if the concurrent presence of the metabolic syndrome might exacerbate this elevation in the levels of these cardiovascular risk markers in subjects with OSAS. With these objectives, the PWV and serum CRP were measured in 184 subjects attending a sleep clinic. It was found that the PWV and CRP were higher in the subjects with OSAS (n =94) than in those without OSAS (n =90). Furthermore, among the subjects with OSAS, the PWV and CRP were higher in those with the concurrent presence of the metabolic syndrome 
Introduction
Obstructive sleep apnea syndrome (OSAS) is frequently associated with some atherosclerotic risk factors, such as hypertension, abnormal glucose metabolism, and obesity, and with increased cardiovascular morbidity and mortality (1) (2) (3) (4) . These risk factors are components of the metabolic syndrome, which has also been shown to be associated with an increased risk of atherosclerotic cardiovascular morbidity and mortality (5) (6) (7) . Thus, while the metabolic syndrome frequently occurs in association with OSAS (8, 9) , no studies have been conducted to evaluate whether the concurrent presence of metabolic syndrome is associated with exacerbation of the atherosclerotic cardiovascular risk in subjects with OSAS. Pulse wave velocity (PWV), which reflects arterial stiffness, has been reported as a marker of future cardiovascular events, independent of the conventional atherosclerotic risk factors (10, 11) . On the other hand, inflammation plays a key role in the progression of atherosclerosis (12) , and the plasma level of C-reactive protein (CRP) has also been noted as a marker of atherosclerotic cardiovascular events (13, 14) . While these markers have been shown to be elevated in both subjects with OSAS (15, 16) and those with the metabolic syndrome (17, 18) , no studies have been conducted to determine whether the concurrent presence of metabolic syndrome and OSAS is associated with additive elevation of these two cardiovascular risk markers. Therefore, the present cross-sectional study was conducted in subjects attending a sleep clinic; the subjects were examined to determine whether the PWV and plasma levels of CRP were elevated in the presence of OSAS, and also to determine if the concurrent presence of the metabolic syndrome was associated with exacerbation of the increase in the PWV and plasma levels of CRP in subjects with OSAS.
Methods

Subjects
A consecutive 184 subjects (143 male and 41 female; age, 50±13 years old), who visited the hospital, an affiliated clinic of the Tokyo Medical University, for the treatment of sleep apnea between November 2002 and June 2004 were enrolled in this study. All of the participants were admitted to the hospital for sleep diagnostic assessments, measurement of the brachial-ankle PWV, and blood examinations under fasting conditions. Informed consent was obtained from all participants, the protocol was approved by the hospital ethics committee, and the study was performed in accordance with the current revision of the Declaration of Helsinki. None of the patients was diagnosed as having central apnea. Before enrolling in this study, six patients who had a medical history of treatment for either coronary heart disease (n= 4) or stroke (n= 2) were excluded.
Definitions
We used the modified National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) criteria (19) for detection of the metabolic syndrome: high-density lipoprotein cholesterol < 1.036 mmol/l (male) and < 1.295 mmol/l (female); triglycerides ≥ 1.695 mmol/l; blood pressure ≥ 130/85 mmHg or current use of antihypertensive drugs; fasting glucose ≥ 6.105 mmol/l; and body mass index ≥ 27.5 (20) (the waist circumference was not available in this study).
Nocturnal Sleep Studies
All the subjects underwent polysomnography (Somno Star α; Sensor Medics, Yorba Linda, USA) in a hospital sleep laboratory. Electroencephalography, electro-oculography, electromyography, and electrocardiography were performed simultaneously and visually scored according to standard criteria (21) . Ventilatory flow at the nose and mouth was measured with thermistors. The arterial oxygen saturation was measured transcutaneously at the fingertip by pulse oximetry. Apnea was defined as a continuous cessation of airflow for more than 10 s, and hypopnea was defined as a 50% reduction in airflow for more than 10 s with an oxygen desaturation of ≥ 4% and a reduction in chest wall movement (22) . The apnea hypopnea index (AHI) was calculated as the total number of episodes of apnea and hypopnea per hour of sleep. An AHI ≥ 15 was considered diagnostic for OSAS. The Epworth Sleepiness Scale (ESS) was used to evaluate daytime sleepiness (23) .
Pulse Wave Velocity and Blood Pressure
Brachial-ankle PWV, bilateral brachial and ankle blood pressure were simultaneously measured using a volume-plethysmographic apparatus (Form/ABI; Colin Co., Ltd., Komaki, Japan) according to a previously described methodology (24, 
25).
This method was validated in a previous report; the intraobserver coefficient of variation was 10.0% (25) .
Laboratory Measurements
The levels of serum creatinine, fasting plasma glucose, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured using enzymatic methods (Falco Biosystems Co., Ltd., Tokyo, Japan). CRP was determined by the latex-aggregation method (Dai-ichi Kagaku, Co., Ltd., Tokyo, Japan), which is a high-sensitivity assay method with a detection threshold of less than 0.1 mg/l. The interassay coefficient of variation for this parameter was 2.9%. All blood samples were obtained in the morning after an overnight fast.
Statistical Analysis
Data were expressed as the mean±SEM. The mean of the brachial-ankle PWV values measured on the right and left sides of each subject was used for the statistical analysis. The differences in the variables among the groups (with and without OSAS/with and without the metabolic syndrome) were assessed using Welch's t-test for continuous variables and the χ 2 test for the distributions of the categorical variables. A general linear model univariate analysis-post hoc comparison was used to assess the differences in the brachial-ankle PWV and plasma levels of CRP among the groups (with and without OSAS/with and without the metabolic syndrome), after adjustment for Model A (age, gender, smoking status, total cholesterol, and medications [antihypertensive drugs and statins]) and Model B (Model A + body mass index). For the brachial-ankle PWV, an additional adjustment (Model C= Model B + mean blood pressure) was also performed. In this analysis, either the brachial-ankle PWV or the plasma levels of CRP was a dependent variable, the group category (either with or without OSAS/with or without the metabolic syndrome) was the fixed factor, and the variables in the adjustments were covariates. In addition, a general linear model univariate analysis-post hoc multiple comparison with Sidak's adjustment was used to assess the differences in the brachial-ankle PWV and plasma levels of CRP among four groups (no-disorder, metabolic syndrome alone, OSAS alone, and OSAS + metabolic syndrome) after adjustment for Model A, Model B, and Model C (only for brachial-ankle PWV). In this analysis, either the brachial-ankle PWV or the plasma levels of CRP was the dependent variable, the group category (no-disorder, metabolic syndrome, OSAS, and OSAS + metabolic syndrome) was the fixed factor, and the variables in the adjustments were covariates. A general linear model univariate analysis was also applied to examine the independence of the association of the metabolic syndrome and OSAS with the two cardiovascular risk factors (brachial-ankle PWV and CRP). In this analysis, in the first step, either the brachialankle PWV or the plasma levels of CRP was set as the dependent variable and metabolic syndrome and OSAS were the fixed factors; then, a custom model of the general linear model analysis was applied. In the next step, the interaction between the metabolic syndrome and OSAS was introduced into this model to test the synergistic effects of the two conditions on the brachial-ankle PWV and the plasma levels of CRP. Finally, adjustments with Model A and Model B were performed. All analyses were conducted using SPSS software for Windows, version 11.0J (SPSS, Chicago, USA). p values of < 0.05 were considered statistically significant. Table 1 shows the clinical characteristics of the subjects with and without OSAS. The atherosclerotic risk parameters were worse in the subjects with OSAS than in those without OSAS. Even after adjustment for Model A, Model B, and Model C (including mean blood pressure), the brachial-ankle PWV and plasma levels of CRP were higher in the subjects with OSAS than in those without OSAS (Fig. 1) . Table 2 shows the clinical characteristics of the subjects with and without concurrent presence of the metabolic syndrome among the subjects with and without OSAS. In both the groups with and without OSAS, the presence of the metabolic syndrome was associated with elevation in the parameters of atherosclerotic risk. Furthermore, even after the adjustments, the brachial-ankle PWV was higher in the subjects with OSAS + metabolic syndrome than in those with OSAS alone (Fig. 2) . While the plasma level of CRP was also higher in the subjects with OSAS + metabolic syndrome than in the subjects with OSAS alone after adjustments conducted without including the body mass index, the difference did not reach the level of statistical significance when the body mass index was taken into consideration for the adjustments (Fig.  3) . In the assessment of the difference of brachial-ankle PWV and the plasma levels of CRP among the four groups (no-disorder, metabolic syndrome, OSAS, and OSAS + metabolic syndrome), the brachial-ankle PWV in the group of subjects with OSAS + metabolic syndrome was higher than that in the other three groups (Fig. 2) . Similarly, while the plasma level of CRP in the group of subjects with OSAS + metabolic syndrome was higher than in the other three groups when the adjustments were conducted without considering the body mass index, the plasma levels of CRP were significantly higher in the subjects with OSAS + metabolic syndrome than in the group of subjects with neither OSAS nor metabolic syndrome (no-disorder) when the adjustment included the body mass index as a covariate (Fig. 3) . Because about 30% of the subjects were receiving statins, which are recognized as powerful modulators of the plasma levels of CRP, a sub-analysis with adjustment for Model B to assess the difference in the plasma levels of CRP among the four groups was performed in the subjects not receiving statins (n= 124). Even in this sub-analysis, when the adjustment was conducted so as to include the body mass index, the plasma levels of CRP were higher in the subjects with OSAS + metabolic syndrome than in those with neither OSAS nor metabolic syndrome (no-disorder) (Fig. 4) . A general linear model univariate analysis showed that the metabolic syndrome and OSAS were independently and significantly associated with both elevated brachial-ankle PWV and increased plasma levels of CRP, after adjustments conducted without consideration of body mass index. In this analysis, no interaction between OSAS and the metabolic syndrome was confirmed for either the brachial-ankle PWV or CRP. However, when adjustments took into consideration the body mass index, while the significance of the OSAS relationships did not change, the independent effect of metabolic syndrome on elevated plasma CRP, but not the independent effect of metabolic syndrome on elevated brachial-ankle PWV, failed to reach the level of statistical significance (Table 3) .
Results
Discussion
This cross-sectional study demonstrated that OSAS was associated with elevation of the brachial-ankle PWV and increase in the plasma levels of CRP, and that the concurrent presence of the metabolic syndrome in subjects with OSAS was associated with exacerbation of the elevations of both the brachial-ankle PWV and the plasma levels of CRP. A general linear model univariate analysis showed that metabolic syndrome and OSAS were significant independent variables for both elevated brachial-ankle PWV and plasma levels of CRP, after adjustments conducted without taking into consideration the body mass index. However, when the adjustment included the body mass index, the independence of the association of the metabolic syndrome with elevated plasma CRP levels did not reach the level of statistical significance.
Aortic PWV is a marker related to the severity of atherosclerosis (26, 27) . Increased central arterial stiffness, reflected by the increase in aortic PWV, increases cardiac wall stress, impairs coronary blood supply via falling diastolic blood pressure, and is an atherogenic factor (27, 28) . These underlying mechanisms support the belief that increased central arterial stiffness is a marker of elevated cardiovascular risk. While arterial stiffness has been shown to be increased in both subjects with OSAS and in those with the metabolic syndrome (15, 17) , the present study is the first to demonstrate that the elevated brachial-ankle PWV in subjects with OSAS is augmented by the concurrent presence of metabolic syndrome. Brachial-ankle PWV has been shown to be closely related to central arterial stiffness (24, 25) . Thus, the concurrent presence of metabolic syndrome seems to exacerbate the cardiovascular risk related to arterial stiffness in subjects with OSAS. Furthermore, this increase was independent of the elevation of blood pressure. Therefore, the functional stiffening of the aterial tree appeared to contribute not only to the blood pressure elevation, but also to the arterial stiffening in our patients with OSAS.
Fig. 2. Difference in brachial-ankle pulse wave velocity between the subjects with and without concurrent metabolic syndrome among the subjects with and without obstructive sleep apnea syndrome (OSAS
In patients with the metabolic syndrome, in addition to the cardiovascular risk factors that comprise the metabolic syndrome (obesity, insulin resistance, dyslipidemia, and the elevation of blood pressure), inflammation, oxidative stress, sympathetic activation, and hemostatic and fibrinolytic abnormalities are thought to act as atherogenic factors (29) . Inflammation is thought to play a major role in most of these effects (12) , which are frequently encountered in subjects with OSAS (8, 16) . In the present study, the plasma levels of CRP were higher in subjects with OSAS than in those without OSAS, and the concurrent presence of the metabolic syndrome augmented this elevation in subjects with OSAS. This augmentation was significant even when adjusted for statin use, which affects CRP. Furthermore, this augmentation was also confirmed in the sub-analysis among the subjects who were not taking statins. CRP is thought to be a marker of systemic inflammation related to atherosclerosis (30) . Furthermore, recent studies have demonstrated that CRP acts as a direct atherogenic factor (31). Thus, our results suggest that the concurrent presence of metabolic syndrome in subjects with OSAS also exacerbates the cardiovascular risk as reflected by the plasma CRP levels. However, after adjustments were conducted with a consideration of the body mass index, which has been reported to affect the plasma level of CRP (32), the significance of this augmentation was blunted. Therefore, the increase of the body mass index associated with the metabolic syndrome might be the primary cause of the increase in cardiovascular risk associated with the metabolic syndrome in subjects with OSAS.
The atherosclerotic risk factors comprising the metabolic syndrome are frequently encountered in subjects with OSAS. Recently, Coughlin et al. demonstrated that OSAS was independently associated with an increase in cardiovascular risk factors that comprise the metabolic syndrome (9) . Based on this finding, they speculated that these cardiovascular risk factors might act to increase the cardiovascular risk in subjects with OSAS, just as in those with the metabolic syndrome. However, whether the elevated cardiovascular risk in subjects with OSAS is due to the coexistence of components of the metabolic syndrome, or represents effects specific to OSAS remains to be evaluated. In the present study, a general linear model (GLM) analysis demonstrated that OSAS and the metabolic syndrome were independently associated with elevated brachial-ankle PWV and elevated plasma levels of CRP. Therefore, OSAS and the metabolic syndrome may independently increase the cardiovascular risk as reflected by elevated PWV and elevated plasma CRP, and these results suggest that the concurrent presence of the metabolic syndrome additively increases the cardiovascular risk in subjects with OSAS.
In subjects with the metabolic syndrome, elevated plasma levels of CRP have been reported to provide additional prognostic information for cardiovascular events (33, 34) ; thus, plasma CRP is thought to be an additive risk in global cardiovascular risk prediction in subjects with the metabolic syndrome. Our previous study demonstrated that elevation of the plasma levels of CRP augmented increases in the brachialankle PWV (35) . In the present study, both the brachial-ankle PWV and the plasma levels of CRP were significantly higher in the subjects with OSAS + metabolic syndrome than in those with the metabolic syndrome alone. These results raise an important issue, namely, whether the concurrent presence of OSAS in subjects with the metabolic syndrome may also contribute to the prognosis in subjects with the metabolic syndrome-that is, whether OSAS is also an additive cardiovascular risk factor in subjects with the metabolic syndrome. However, the subjects of this study comprised a specific cohort consisting of subjects visiting a sleep clinic, and thus further studies will be needed to clarify this issue in a general cohort that also includes subjects with the metabolic syndrome.
The present study had some limitations. 1) This was a cross-sectional study and only demonstrated the worsening of surrogate markers of the prognosis in subjects with OSAS who also satisfied the criteria of metabolic syndrome. 2) We used modified criteria for the clinical detection of the metabolic syndrome, in accordance with the reports of Satter et al. (33) and Lee et al. (35) , because waist circumference mea- (36, 37) . Therefore, the significance of central obesity as a determinant of either arterial stiffness or the plasma level of CRP should be evaluated in future studies.
3) The present study did not deal with the precise mechanisms underlying the exacerbation of elevated arterial stiffness and plasma levels of CRP in the concurrent presence of the metabolic syndrome in subjects with OSAS. However, sympathetic tone is a major determinant of arterial stiffness and is also believed to play a role in vascular inflammation (38, 39) . Activation of the sympathetic tone is noted not only in the metabolic syndrome, but also in OSAS. Thus, augmentation of sympathetic activation may be one of the plausible mechanisms underlying the augmented increase of the PWV and plasma CRP in the presence of both metabolic syndrome and OSAS.
In conclusion, the present study demonstrated elevated brachial-ankle PWV and plasma levels of CRP in subjects with OSAS and, furthermore, that the concurrent presence of the metabolic syndrome in subjects augmented this elevation of the brachial-ankle PWV and plasma levels of CRP in subjects with OSAS. OSAS and metabolic syndrome were found to be independently associated with elevation of the brachial-ankle PWV and plasma levels of CRP; however, the increased body mass index that constitutes one of the components of the metabolic syndrome might be the major factor contributing to the elevation of the plasma CRP level in these patients. Thus, OSAS seems to increase the cardiovascular risk as reflected by elevated PWV and elevated plasma CRP. The concurrent presence of the metabolic syndrome in subjects with OSAS may exacerbate the cardiovascular risk reflected by increased arterial stiffness, and increased body mass index, which is a component of the metabolic syndrome, may exacerbate the cardiovascular risk related to an increased plasma level of CRP. Therefore, the concurrent presence of the metabolic syndrome may constitute an additive cardiovascular risk factor in subjects with OSAS. Thus, examination to detect the concurrent presence of the metabolic syndrome is warranted in the management of patients with OSAS.
